Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidotes01:17

Antidotes

1.3K
Antidotes are medicinal substances used to counteract the harmful effects of toxins or drugs in the body. They function in various ways, each uniquely designed to combat specific toxic compounds.
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
1.3K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

1.0K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.0K
Diphtheria01:28

Diphtheria

37
Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
37
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

657
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
657
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

786
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
786
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Entrance-Site Ablation in Atrial Tachycardia Involving Epicardial Conduction: A Case Series.

Journal of arrhythmia·2026
Same author

IL-8 contributes to postoperative adhesion formation through the crosstalk of neutrophils and mesothelial cells.

Scientific reports·2026
Same author

Reduced ADP-induced platelet aggregation may predict poor clinical outcomes in patients with COVID-19.

Thrombosis research·2025
Same author

Prospective Multicenter Registry to Investigate the Clinical Feasibility of Combination Workflow With 90 W/4 s and Ablation Index-Guided 50 W Ablation (PRECISE-COMBO 90 W/50 W Study).

Journal of arrhythmia·2025
Same author

The Efficacy of 2-Week Holter Monitoring for Detecting Atrial Tachyarrhythmia Recurrence After Initial Ablation in Patients With Atrial Fibrillation.

Journal of arrhythmia·2025
Same author

Cognitive Impairment as a Predictor of Long-Term Outcomes in Septic Patients: A Retrospective Observational Study.

Cureus·2025

Related Experiment Video

Updated: Mar 25, 2026

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.4K

[Anti DIC therapy].

Mayuko Yahata, Yuichiro Sakamoto

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |February 27, 2016
    PubMed
    Summary

    Disseminated intravascular coagulation (DIC) involves unbalanced coagulation and fibrinolysis. Treatment choice, including anticoagulation or antifibrinolytic therapy, depends on the underlying cause like sepsis or trauma, considering drug properties.

    Area of Science:

    • Hematology
    • Critical Care Medicine
    • Pharmacology

    Background:

    • Disseminated intravascular coagulation (DIC) is a complex syndrome characterized by dysregulated activation of coagulation and fibrinolysis.
    • Unbalanced activation of these systems leads to widespread microthrombi formation and consumption of clotting factors and platelets.
    • DIC can arise from various conditions, including sepsis and trauma, necessitating tailored therapeutic approaches.

    Purpose of the Study:

    • To review the therapeutic strategies for disseminated intravascular coagulation (DIC).
    • To highlight the importance of selecting appropriate anti-DIC agents based on their pharmacological properties.
    • To discuss the differential indications for anticoagulation and antifibrinolytic therapy in DIC.

    Main Methods:

    More Related Videos

    Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
    14:18

    Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

    Published on: October 13, 2023

    2.0K
    Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
    05:21

    Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay

    Published on: September 13, 2024

    1.0K

    Related Experiment Videos

    Last Updated: Mar 25, 2026

    Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
    09:39

    Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

    Published on: September 17, 2019

    7.4K
    Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
    14:18

    Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

    Published on: October 13, 2023

    2.0K
    Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
    05:21

    Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay

    Published on: September 13, 2024

    1.0K
  • Literature review of current therapeutic options for DIC.
  • Analysis of the role of anticoagulation and antifibrinolytic therapies in different DIC etiologies.
  • Consideration of pharmacological properties of available anti-DIC agents.

    • Main Results:

    • Auxiliary treatments can improve outcomes in DIC when used alongside primary disease management.
    • Anticoagulation is indicated in sepsis-induced DIC where coagulation activation predominates.
    • In trauma-associated DIC, where coagulation and fibrinolysis balance is rapidly disrupted, both anticoagulation and antifibrinolytic therapies may be employed based on clinical status.

    Conclusions:

    • The choice of anti-DIC agents requires careful consideration of their pharmacological profiles.
    • Tailoring treatment strategies, including anticoagulation and antifibrinolysis, to the specific cause of DIC is crucial for effective management.
    • Understanding the distinct pathophysiological mechanisms in sepsis- and trauma-induced DIC guides therapeutic decision-making.